REGINfo: Biogen Idec Inc - Biotechnologie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

S&P 100 NEWS

> 21st Century Fox Inc

> Accenture PLC

> Allstate Corp.

> Altria Group, Inc.

> Amazon.com Inc

> American Express

> American International Group

> Bank of America

> Bank of New York Mellon Corp

> Berkshire Hathaway Inc.

> Biogen Idec Inc

> Booking Holdings

> Bristol-Myers Squibb Co.

> Caterpillar Inc.

> Charter Communication

> Cisco Systems Inc

> Coca Cola Co.

> Colgate-Palmolive

> ConocoPhillips

> Costco Wholesale Corp

> CVS Caremark Corp.

> Eli Lilly & Co.

> Emerson Electric Co.

> Exelon Corporation

> Exxon Mobil Corp.

> Ford Motor Company

> General Dynamics

> General Electric

> General Motors

> Gilead Sciences Inc

> Goldman Sachs Group, Inc.

> Halliburton Co.

> Home Depot, Inc

> Honeywell International, Inc.

> International Business Machines (IBM)

> Johnson & Johnson

> JP Morgan Chase & Co

> Kinder Morgan Inc

> Lockheed Martin

> Lowes Companies

> Mastercard Inc A

> McDonald's Corp.

> Medtronic, Inc.

> Merck & Co., Inc.

> Mondelez International Inc

> Morgan Stanley

> NextEra Energy Inc

> ...

FEEDS

My Google

Microsoft Live

My Yahoo

COMPANY SEARCH RESULT

$Biogen Idec Inc: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2019.04.12 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference - HTML (w)

2019.03.21 | 12:00 | Permanent Information Releases / General Company News

puce Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease - HTML (w)

2019.03.12 | 08:00 | Permanent Information Releases / General Company News

puce Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm - HTML (w)

2019.03.04 | 08:00 | Permanent Information Releases / General Company News

puce Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology - HTML (w)

2019.02.28 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy - HTML (w)

2019.02.25 | 13:30 | Permanent Information Releases / General Company News

puce Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis - HTML (w)

2019.02.06 | Periodic information / Annual Financial Report

puce Biogen Idec Inc : ANNUAL REPORT 2018 - Form 10-K - PDF (3Mb)

2019.01.04 | 13:30 | Permanent Information Releases / General Company News

puce Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets - HTML (w)

2019.01.04 | 13:30 | Permanent Information Releases / General Company News

puce Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions - HTML (w)

2019.01.03 | 13:30 | Permanent Information Releases / General Company News

puce First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis - HTML (w)

2018.12.17 | 13:30 | Permanent Information Releases / General Company News

puce Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis - HTML (w)

2018.12.06 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data - HTML (w)

2018.11.29 | 13:30 | Permanent Information Releases / General Company News

puce International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product - HTML (w)

2018.10.25 | 14:31 | Permanent Information Releases / General Company News

puce Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference - HTML (w)

2018.10.23 | 07:00 | Permanent Information Releases / General Company News

puce UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus - HTML (w)

Pages : 1 - 2 - 3 - 4 / Doc nb : 50